Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Appointed director

Predictive Oncology Inc. (AIPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/10/2023 8-K Quarterly results
Docs: "Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights: Initiated PEDAL-Cancer Research Horizons collabor..."
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/15/2023 8-K Quarterly results
Docs: "Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three months ended March 31, 2023, and provided a corporate update. The company reported a net loss of $3.4 million on total net revenue of $0.2 million for the first quarter 2023. Q1 2023 and Recent Highlights: Announced groundbreaking partnership with Cancer Research Ho..."
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Regulation FD Disclosure  Interactive Data
05/02/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/05/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
03/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/21/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EAGAN, Minn., March 21, 2023 -- Predictive Oncology Inc. , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments laboratory and Good Manufacturing Practices facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update. The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year. 2022 Highlights: Successfully completed Discovery 21, establishing proof-of-concept for the PEDAL™ drug discover..."
03/21/2023 10-K Annual Report for the period ended December 31, 2022
03/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/16/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock"
03/16/2023 8-A12G Form 8-A12G - Registration of securities [Section 12(g)]:
03/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development"
03/13/2023 8-K Other Events  Interactive Data
02/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 -- Predictive Oncology Inc. is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company’s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company’s biopharma partners. “In terms of scientific intelligence, industry insi..."
12/05/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
10/18/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/18/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/14/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/13/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/30/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
09/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition and Separation Agreement by and between J. Melville Engle and Predictive Oncology Inc",
"Predictive Oncology Announces CEO Retirement"
09/14/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to Second Amended and Restated Bylaws of Predictive Oncology Inc."
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy